Application of combination therapy for treating glioblastoma
DOI:
https://doi.org/10.62051/an3dhj30Keywords:
Glioblastoma; Immunotherapy; Therapeutic vaccine; Adjuvants; Neoadjuvants.Abstract
Glioblastoma (GBM), an aggressive brain tumor with a high mortality rate, is also extremely easy to differentiate and metastasize, making it one of the most dangerous cancers in the world. The aim of this research was to establish a unique combination therapy that combines surgery and vaccination to treat GBM. This research uses predictive clinical trials and artificial intelligence analytics to summarize and examine the side effects and remedies of combination therapy, thus ensuring the physical and mental health of patients and aiming to create a low-cost treatment with a high success rate. Since angiogenesis is the most challenging side effect to treat, other remedies for this symptom were also summarized in this research. This means that this combination therapy may provide better success rates and a more patient-appropriate course of care compared to earlier approaches. It is hoped that in the coming time, this combination treatment plan will be adopted and implemented, and it is hoped that more efficient treatment methods will be proposed so that all GBM patients can be cured.
Downloads
References
[1] H. Sung, J. Ferlay, R. L. Siegel, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 71(3) (2021) 209-249.
[2] I. Ilic, M. Ilic, International patterns and trends in the brain cancer incidence and mortality: An observational study based on the global burden of disease. Heliyon 9(7) (2023) e18222.
[3] L. B. E. Shields, A. K. Choucair Management of low-grade gliomas: a review of patient-perceived quality of life and neurocognitive outcome. World neurosurgery 82(1-2) (2014) e299-e309.
[4] A. Malmström, B. H. Grønberg, C. Marosi, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. The lancet oncology 13(9) (2012) 916-926.
[5] K. Mitusova, O. O. Peltek, T. E. Karpov, et al. Overcoming the blood–brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches. Journal of nanobiotechnology 20(1) (2022) 412.
[6] M. G. McNamara, S. Sahebjam, W. P. Mason, Emerging biomarkers in glioblastoma. Cancers 5(3) (2013) 1103-1119.
[7] H. Zhang, R. Wang, Y. Yu, et al. Glioblastoma treatment modalities besides surgery. Journal of Cancer 10(20) (2019) 4793.
[8] J. Yang, Z. Shi, R. Liu, et al. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology. Theranostics 10(7) (2020) 3223.
[9] R. M. Young, A. Jamshidi, G. Davis, et al. Current trends in the surgical management and treatment of adult glioblastoma. Annals of translational medicine 3(9) (2015) 121.
[10] Clinical Research, U.S. Food & Drug Administration https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
[11] A. Datsi, R. V. Sorg, Dendritic cell vaccination of glioblastoma: road to success or dead end. Frontiers in Immunology 12 (2021) 770390.
[12] E. Fountzilas, R. Said, A. M. Tsimberidou, Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits. Expert opinion on investigational drugs 27(2) (2018) 155-162.
[13] A. Hamad, G. M. Yusubalieva, V. P. Baklaushev, et al. Recent developments in glioblastoma therapy: oncolytic viruses and emerging future strategies. Viruses 15(2) (2023) 547.
[14] Z. Kong, Y. Wang, W. Ma, Vaccination in the immunotherapy of glioblastoma. Human vaccines & immunotherapeutics 14(2) (2018) 255-268.
[15] M. Weller, P. Roth, M. Preusser, et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nature Reviews Neurology 13(6) (2017) 363-374.
[16] M. Kocher, M. I. Ruge, N. Galldiks, et al. Applications of radiomics and machine learning for radiotherapy of malignant brain tumors. Strahlentherapie und Onkologie 196 (2020) 856-867.
[17] P. Ståhl, I. Henoch, A. Smits, et al. Quality of life in patients with glioblastoma and their relatives. Acta Neurologica Scandinavica 146(1) (2022) 82-91.
[18] T. Sakata, M. Tanikawa, H. Yamada, et al. Minimally invasive treatment for glioblastoma through endoscopic surgery including tumor embolization when necessary: a technical note. Frontiers in Neurology 14 (2023) 1170045.
[19] T. Aoki, N. Hashimoto, M. Matsutani, Management of glioblastoma. Expert opinion on pharmacotherapy 8(18) (2007) 3133-3146.
[20] S. Polyzoidis, J. Tuazon, L. Brazil, et al. Active dendritic cell immunotherapy for glioblastoma: Current status and challenges. British journal of neurosurgery 29(2) (2015) 197-205.
[21] I. F. Parney, S. M. Chang. Current chemotherapy for glioblastoma. The Cancer Journal 9(3) (2003) 149-156.
[22] P. D. Delgado-López, E. M. Corrales-García, Survival in glioblastoma: a review on the impact of treatment modalities. Clinical and Translational Oncology 18(11) (2016) 1062-1071.
[23] T. A. Lawrie, D. Gillespie, T. Dowswell, et al. Long‐term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma. Cochrane Database of Systematic Reviews 8 (2019) No.: CD013047.
[24] F. Winkler, M. Osswald, W. Wick, Anti-angiogenics: their role in the treatment of glioblastoma. Oncology research and treatment 41(4) (2017) 181-186.
[25] J. J. C. Verhoeff, O. Van Tellingen, A. Claes, et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC cancer 9 (2009) 1-9.
[26] A. B. Zhang, K. Mozaffari, B. Aguirre, et al. Exploring the past, present, and future of anti-angiogenic therapy in glioblastoma. Cancers 15(3) (2023) 830.
[27] S. Keller, M. H. H. Schmidt, EGFR and EGFRvIII promote angiogenesis and cell invasion in glioblastoma: combination therapies for an effective treatment. International journal of molecular sciences 18(6) (2017) 1295.
Downloads
Published
Conference Proceedings Volume
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
